Cargando…

Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma

Targeting oncogenic fusion-genes in pediatric high-grade gliomas (pHGG) with entrectinib has emerged as a highly promising therapeutic approach. Despite ongoing clinical studies, to date, no reports on the treatment of cerebrospinal fluid (CSF) disseminated fusion-positive pHGG exist. Moreover, clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mayr, Lisa, Guntner, Armin S., Madlener, Sibylle, Schmook, Maria T., Peyrl, Andreas, Azizi, Amedeo A., Dieckmann, Karin, Reisinger, Dominik, Stepien, Natalia M., Schramm, Kathrin, Laemmerer, Anna, Jones, David T. W., Ecker, Jonas, Sahm, Felix, Milde, Till, Pajtler, Kristian W., Blattner-Johnson, Mirjam, Strbac, Miroslav, Dorfer, Christian, Czech, Thomas, Kirchhofer, Dominik, Gabler, Lisa, Berger, Walter, Haberler, Christine, Müllauer, Leonhard, Buchberger, Wolfgang, Slavc, Irene, Lötsch-Gojo, Daniela, Gojo, Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766483/ https://www.ncbi.nlm.nih.gov/pubmed/33353026 http://dx.doi.org/10.3390/jpm10040290

Ejemplares similares

ETMR-10. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY AND DELAYED RADIOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR)
por: Mayr, Lisa, et al.
Publicado: (2020)

RARE-20. A RARE CASE OF A PRIMARY CENTRAL NERVOUS SYSTEM NEUROENDOCRINE CARCINOMA AND SUCCESSFULL THERAPY IN A FIVE-YEAR-OLD CHILD
por: Stepien, Natalia, et al.
Publicado: (2021)

Unique Finding of a Primary Central Nervous System Neuroendocrine Carcinoma in a 5-Year-Old Child: A Case Report
por: Stepien, Natalia, et al.
Publicado: (2022)

DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS
por: Stepien, Natalia, et al.
Publicado: (2020)

Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients
por: Guntner, Armin Sebastian, et al.
Publicado: (2020)

Novel Insights into Diagnosis, Biology, and Treatment of Primary Diffuse Leptomeningeal Melanomatosis
por: Baumgartner, Alicia, et al.
Publicado: (2021)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

HGG-50. Specific sensitivity of pediatric high-grade glioma with ATRX inactivation to PARP inhibitor combinations
por: Laemmerer, Anna, et al.
Publicado: (2022)

ETMR-11. Transcriptional changes upon knockdown of alteredBCOR/BCORL1 transcripts in preclinical models of CNS embryonal tumors with BCOR-related alterations
por: Piontek, Martin, et al.
Publicado: (2022)

Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC-Amplified Group 3 Medulloblastoma by Droplet Digital PCR
por: Stepien, Natalia, et al.
Publicado: (2023)

Clinical applicability of miR517a detection in liquid biopsies of ETMR patients
por: Madlener, Sibylle, et al.
Publicado: (2023)

ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS
por: Madlener, Sibylle, et al.
Publicado: (2023)

ETMR-12. Novel cell models of CNS tumors with BCOR fusion or internal tandem duplication suggest FGFR and PDGFR as promising therapy targets
por: Kirchhofer, Dominik, et al.
Publicado: (2022)

Targeting fibroblast growth factor receptors to combat aggressive ependymoma
por: Lötsch, Daniela, et al.
Publicado: (2021)

Potential Importance of Early Focal Radiotherapy Following Gross Total Resection for Long-Term Survival in Children With Embryonal Tumors With Multilayered Rosettes
por: Mayr, Lisa, et al.
Publicado: (2020)

HGG-08. COMBINATORIAL ACTIVITY OF CDK4/6-INHIBITORS AND TRAMETINIB IN PEDIATRIC HIGH-GRADE GLIOMA WITH BRAFV600E MUTATION AND HOMOZYGOUS CDKN2A DELETION
por: Mayr, Lisa, et al.
Publicado: (2023)

Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas
por: Dorfer, Christian, et al.
Publicado: (2020)

HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS
por: Haberler, Christine, et al.
Publicado: (2020)

SURG-02. The site of origin of medulloblastoma: Does the neurosurgical perspective support the current concept from molecular data?
por: Ciobanu-Caraus, Olga, et al.
Publicado: (2022)

p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction
por: Dinhof, Carina, et al.
Publicado: (2020)

Placement of EVD in pediatric posterior fossa tumors: safe and efficient or old-fashioned? The Vienna experience
por: Hedrich, Cora, et al.
Publicado: (2023)

Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies
por: Gojo, Johannes, et al.
Publicado: (2017)

Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a “MEMMAT-like” Metronomic Antiangiogenic Approach
por: Slavc, Irene, et al.
Publicado: (2022)

MBCL-43. RECURRENT MEDULLOBLASTOMA – LONG-TERM SURVIVAL WITH A “MEMMAT” BASED ANTIANGIOGENIC APPROACH
por: Slavc, Irene, et al.
Publicado: (2020)

EPEN-23. Interaction of epigenetic regulation and telomerase re-activation in high-risk ependymoma
por: Jaunecker, Carola N, et al.
Publicado: (2022)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma
por: Araki, Asuka, et al.
Publicado: (2016)

High impact of miRNA-4521 on FOXM1 expression in medulloblastoma
por: Senfter, Daniel, et al.
Publicado: (2019)

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion
por: Kurozumi, Kazuhiko, et al.
Publicado: (2022)

The Site of Origin of Medulloblastoma: Surgical Observations Correlated to Molecular Groups
por: Ciobanu-Caraus, Olga, et al.
Publicado: (2023)

Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities
por: Gojo, Johannes, et al.
Publicado: (2020)

TRLS-08. EXPERIENCE WITH THE SELECTIVE FIBROBLAST GROWTH FACTOR INHIBITOR ERDAFITINIB IN THREE PEDIATRIC PATIENTS WITH CNS TUMORS
por: Stepien, Natalia, et al.
Publicado: (2023)

The experience of successful treatment of ETV6-NTRK3-positive infant glioblastoma with entrectinib
por: Papusha, Ludmila, et al.
Publicado: (2021)

Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma
por: Grogan, Patrick T, et al.
Publicado: (2022)

DDEL-05. Intraventricular therapy with topotecan is feasible and safe: Experience in 50 pediatric patients with various malignant brain tumors
por: Peyrl, Andreas, et al.
Publicado: (2022)

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
por: Farago, Anna F., et al.
Publicado: (2015)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pb2mrgiknt58a0kf0e63um3bss